<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02964065</url>
  </required_header>
  <id_info>
    <org_study_id>F20160728</org_study_id>
    <nct_id>NCT02964065</nct_id>
  </id_info>
  <brief_title>A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun BCHT Biotechnology Co.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simoon Record Pharma Information Consulting Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baoding Municipal Center for Disease Control and Prevention, Hebei, P.R.China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maoming Municipal Center for Disease Control and Prevention, Guangdong, P.R.China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Medical Statistics, Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changchun BCHT Biotechnology Co.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial to&#xD;
      evaluate the efficacy, safety and immunogenicity of a single dose of Live-Attenuated&#xD;
      influenza Vaccine(LAIV) among healthy children and adolescents aged 3-17 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial to&#xD;
      evaluate the efficacy, safety and immunogenicity of a single dose of Live-Attenuated&#xD;
      influenza Vaccine(LAIV) among healthy children and adolescents aged 3-17 years old. The&#xD;
      subjects will be randomized in a 1:1 ratio of LAIV to placebo. Each subject will be&#xD;
      vaccinated with a single dose of LAIV or Placebo. For evaluation of efficacy, subjects&#xD;
      meeting the protocol-defined clinical case definition the 14th day post-vaccination will have&#xD;
      a nasal swab collected for testing by RT-PCR or virus culture for evidence of influenza virus&#xD;
      infection. All adverse events will be collected 30 minutes, 0-30 days after vaccination and&#xD;
      all serious adverse events during the entire trial period. Blood samples will be collected&#xD;
      from a part of subjects before vaccination and at the 30th day after immunization. Serum&#xD;
      samples will be centrifuged for detection of antibodies to H1N1, H3N2, and influenza B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Symptomatic, Laboratory-confirmed(RT-PCR/ Virus Culture) Influenza Virus Infection(Vaccine-like Strains)</measure>
    <time_frame>Through 2 weeks to 1 year post vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Symptomatic, Laboratory-confirmed(RT-PCR/ Virus Culture) Influenza Virus Infection(Regardless of Vaccine Match)</measure>
    <time_frame>Through 2 weeks to 1 year post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects with influenza-like illness caused by Influenza Virus Infection(Laboratory-confirmed by RT-PCR/ Virus Culture)</measure>
    <time_frame>Through 2 weeks to 1 year post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Occurring Within 30 Minutes of Administration of Study Vaccine</measure>
    <time_frame>Through 30 minutes post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Adverse Events</measure>
    <time_frame>Through 14 days post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited Adverse Events</measure>
    <time_frame>Through 30 days post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) of Hemagglutination Inhibition (HAI) Antibodies to each of the Influenza Strains in the Vaccine Received</measure>
    <time_frame>30 days post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with antibody positive conversion to each of the Influenza Strains in the Vaccine Received.</measure>
    <time_frame>30 days post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9000</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>LAIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live-Attenuated influenza Vaccine(LAIV)</intervention_name>
    <arm_group_label>LAIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy children and adolescents aged 3-17 years old.&#xD;
&#xD;
          2. Informed consent obtained and signed by subjects or legal guardians prior to&#xD;
             screening. Children or adolescents aged 10-17 yrs need sign informed consent by&#xD;
             themselves.&#xD;
&#xD;
          3. Willing to participate for the planned duration of the study, including availability&#xD;
             for follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any investigational or unregistered product (drug, vaccine or device) was used within&#xD;
             30 days, or planned to be used during the trial.&#xD;
&#xD;
          2. have been vaccinated with any influenza vaccine within 6 months, or plan to be&#xD;
             vaccinated during the trail.&#xD;
&#xD;
          3. Immunosuppressive agents or other immunomodulatory drugs (defined as continuous use&#xD;
             for more than 14 days) were used over a 3-month period.&#xD;
&#xD;
          4. Immunoglobulins and / or any blood products were used within 3 months, or planned to&#xD;
             be used before blood collection.&#xD;
&#xD;
          5. History of Guillain-Barré syndrome; History of hypersensitivity to any component of&#xD;
             the LAIV, including egg or egg products.&#xD;
&#xD;
          6. Severe allergic reactions after vaccination (including anaphylactic shock, allergic&#xD;
             laryngeal edema, allergic purpura, local allergic necrosis).&#xD;
&#xD;
          7. Acute diseases , infections or febrile diseases (axillary temperature ≥37.1℃) on the&#xD;
             day of vaccination.&#xD;
&#xD;
          8. Obvious coagulation dysfunction or History of anticoagulant therapy&#xD;
&#xD;
          9. Aspirin is being used(Salicylates are a potential risk factor for Reye syndrome)&#xD;
&#xD;
         10. Known or suspected immune deficiency diseases or immunosuppressed&#xD;
&#xD;
         11. Heart disease, respiratory diseases (including severe rhinitis, nasal deformities,&#xD;
             polyps, etc.), liver disease, kidney disease, mental disorders, chronic infections&#xD;
             etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangdong Provincial Institute of Biological Products and Materia Media</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>511430</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Shijiazhuang Shi</city>
        <state>Hebei</state>
        <zip>050021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccines</keyword>
  <keyword>LAIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

